化湿败毒颗粒治疗新型冠状病毒肺炎的药物经济学评价OA

Objective To evaluate the economy of Huashin baidu granule in the treatment of coroma virus disease 2019,and to provide reference for rational drug use and optimization of treatment plan in the clinical treatment of COVID-19.Methods From the perspective of the whole society,a decision tree model was constructed to analyze the cost-effectiveness of Huashui baidu granule combined with basic treatment compared with basic treatment.The output index was QALY.Cost data came from the enterprise and related literature,and effect data came from randomized controlled trial(RCT)studies and related literature.The robustness of the results is analyzed by single factor sensitivity analysis and probability sensitivity analysis.Results Compared with the basic treatment,Huashi baidu granule combined with basic treatment had lower cost(19 608.94 yuan VS 20 828.36 yuan)and better effect(0.931 2 QALYs VS 0.929 5 QALYs)in the treatment of COVID-19 in mild ordinary patients.ICUR is-709 471.85 yuan/QALY;For severe patients,the cost was low(67 951.65 yuan VS 70 074.58 yuan)and the effect was high(0.880 0 QALYs VS 0.874 8 QALYs),with an ICUR of-408 504.73 yuan/QALY.Sensitivity analysis showed that the results were robust.Conclusion Huashi baidu granule combined with basic treatment has a good therapeutic effect in the treatment of coroma virus disease 2019,which is a pharmacoeconomic advantage in clinical treatment.